Update: Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection

MT Newswires Live
09/22

(Updates with the latest stock price movement in the headline and the first paragraph.)

Amneal Pharmaceuticals (AMRX) shares rose more than 10% in Monday trading after the company said Friday the US Food and Drug Administration approved its lanreotide injection, 120 mg/0.5 mL.

The company said it will immediately launch the product, which references SOMATULINE Depot and received Competitive Generic Therapy designation from the FDA.

Lanreotide injection is indicated for the treatment of acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors and carcinoid syndrome, according to a statement.

Price: 20.62, Change: +1.91, Percent Change: +10.18

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10